Navigation Links
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/17/2008

is C patients with moderate to severe fibrosis or cirrhosis who failed prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy were retreated with PEGINTRON combination therapy. PEGINTRON combination therapy is the first and only pegylated interferon combination therapy approved in the European Union (EU) for retreating both hepatitis C relapsers and nonresponders.

Researchers also will present the final results of the COPILOT study, which evaluated the investigational use of low-dose PEGINTRON as maintenance therapy in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. The goal of maintenance therapy in this very hard-to-treat patient population is to prevent or delay the progression of liver disease, liver cancer or death.

Schering-Plough also is exploring novel therapeutic approaches to treating hepatitis C with boceprevir, its investigational oral HCV protease inhibitor currently in Phase II clinical development. Oral presentations of boceprevir data will include interim results from the HCV SPRINT-1 study in treatment-naive hepatitis C patients and final results of the HCV RESPOND-1 study in patients who were "null" responders to previous peginterferon and ribavirin combination therapy.

Key Data Presentations at EASL

PEGINTRON Oral Presentations

Final results of the IDEAL (Individualized Dosing Efficacy versus flat dosing to Assess optimaL pegylated interferon therapy) Phase IIIb study. Sulkowski, M. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 4:45 p.m. Hall A.

Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previous alfa interferon/ribavirin (I/R) nonresponders (NR): final results from the EPIC3 program. Poynard, T. et al. Late-Breaker Parallel Session 16, Saturday, April 26, 4:00 p.m. Hall A.

Colchicine versus peginterferon alfa 2b long term therapy: results of the 4 year COPILOT trial.
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
2. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
3. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
4. Schering-Plough Reports Top-Line Results of the IDEAL Study
5. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
6. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
7. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
8. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
11. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today issued the following open letter to ... , Dr. Med. Sc. Dear RXi ... a number of inaccurate statements posted on certain ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
(Date:12/24/2014)... Today, Yunx.co.uk, a hot style dress ... other special occasion outfits, unveils 65 new bridesmaid ... at discounted prices, up to 80% off. , Yunx.co.uk’s ... their fashionable designs, gorgeous looks and delicate craftsmanship. These ... is devoted to designing and offering high-quality women’s dresses ...
(Date:12/24/2014)... a famous bamboo flooring company offering bamboo flooring products ... its multiple layer bamboo panel board collection , and ... Bamboo panel is the product made from 100 percent ... features high quality selective bamboo and eco-friendly adhesives that ... consists of multiple layers of bamboo. , According to ...
(Date:12/24/2014)... Hepatitis C infection does not contribute to mental decline in ... advances have made it possible for people with HIV to ... mood swings and other types of mental impairment as they ... infections with other viruses -- a common problem in people ... prime suspects has been the hepatitis C virus, which infects ...
(Date:12/24/2014)... News) -- Researchers say they have used human embryonic ... and sperm. While this had already been done ... that these types of cells -- called primordial germ ... cells, according to the team at the University of ... cells is one of the earliest events during early ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... (ADA) call for giving the cholesterol-lowering drugs known as statins ... These new standards bring the association in line with ... also recommend giving low- or high-dose statins to all people ... "We agree that the decision to start a statin should ...
Breaking Medicine News(10 mins):Health News:Yunx.co.uk Unveils 65 New Bridesmaid Dresses for the UK market 2Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3
... according to a new study. This is a significant finding ... increased and remained unchanged among black women during the last ... Sept. 24, issue of JAMA ( Journal of ... by David A. Lieberman, M.D., head of gastroenterology, Oregon Health ...
... ALEXANDRIA, Va., Sept. 24 The nation,s,leading association ... the importance of respecting the end of life ... President and CEO of the Assisted Living Federation,of ... seniors,know what is best for them in testimony ...
... by union and nonunion caregivers blends online,phone-bank technology ... WASHINGTON, Sept. 24 With women voters,poised to ... a unique,project of SEIU Healthcare will reach at ... workforce -- through worker-to-worker,communication on the candidates, views ...
... markers were analyzed in 83 cases of colorectal ... chain reaction (PCR). PCR products were eletrophoresed on ... Genotype 3.7 software were used for loss of ... features, significant relationship was observed between LOH frequencies ...
... 24 Americans United for Life,(AUL) has filed ... Services,(HHS) affirming the need for a proposed regulation ... providers nationwide., Dr. Charmaine Yoest, President and ... providers is critical to the continuing viability and,safety ...
... Sept. 24 PartsSource, the nation,s,leading supplier of replacement ... fastest growing company on the 2008 INC 500,for healthcare. ... recognized by INC magazine as one of the fastest ... have a publication as esteemed as INC,magazine recognize our ...
Cached Medicine News:Health News:Black Americans are at higher risk for colon polyps 2Health News:ALFA Honors End of Life Choices 2Health News:Nurses, Healthcare Workers Launch Massive Drive to Inform 1 Million Caregivers in Key States on Obama and McCain Healthcare Plans 2Health News:LOH analysis on 4q in sporadic colorectal carcinoma 2Health News:Conscience Protections Essential to Healthcare System, Americans United for Life Argues in Comments Filed with HHS 2
... million people are diagnosed with varicose veins ... patients never seek treament and are apprehensive ... offer them an effective alternative to conventional ... or hook phlebectomy), is considered a laborious ...
...
Inquire...
... in a Compact Size , Featuring design ... along with Alokas latest proprietary electronic technologies, ... portable units suffer from hardware and software ... sets new standards for whats possible in ...
Medicine Products: